These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 9879391

  • 1. [Sibutramine, an upcoming drug for weight loss acting on energy consumption and energy expenditure].
    Astrup A.
    Acta Med Austriaca; 1998; 25(4-5):146-9. PubMed ID: 9879391
    [Abstract] [Full Text] [Related]

  • 2. What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice.
    Astrup A, Lundsgaard C.
    Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 2():29-34. PubMed ID: 9792479
    [Abstract] [Full Text] [Related]

  • 3. Sibutramine: new preparation. Slight weight loss; but also a slight rise in blood pressure ..
    Prescrire Int; 2001 Oct; 10(55):140-5. PubMed ID: 11824428
    [Abstract] [Full Text] [Related]

  • 4. Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment.
    Van Gaal LF, Wauters MA, De Leeuw IH.
    Exp Clin Endocrinol Diabetes; 1998 Oct; 106 Suppl 2():35-40. PubMed ID: 9792480
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials.
    Kim SH, Lee YM, Jee SH, Nam CM.
    Obes Res; 2003 Sep; 11(9):1116-23. PubMed ID: 12972682
    [Abstract] [Full Text] [Related]

  • 7. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
    Mathus-Vliegen EM, Balance Study Group.
    Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
    [Abstract] [Full Text] [Related]

  • 8. Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success.
    Elfhag K, Finer N, Rössner S.
    Diabetes Obes Metab; 2008 Jun; 10(6):498-505. PubMed ID: 17593239
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ, Leibowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, McMahon FG, Mullican WS, Toth PD, Cutler NR.
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [Abstract] [Full Text] [Related]

  • 10. The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women.
    Halford JC, Boyland EJ, Cooper SJ, Dovey TM, Huda MS, Dourish CT, Dawson GR, Wilding JP.
    J Psychopharmacol; 2010 Jan; 24(1):99-109. PubMed ID: 18755818
    [Abstract] [Full Text] [Related]

  • 11. Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients.
    Early JL, Apovian CM, Aronne LJ, Fernstrom MH, Frank A, Greenway FL, Heber D, Kushner RF, Cwik KM, Walch JK, Hewkin AC, Blakesley V.
    Obesity (Silver Spring); 2007 Jun; 15(6):1464-72. PubMed ID: 17557984
    [Abstract] [Full Text] [Related]

  • 12. Long-term pharmacotherapy for obesity.
    Klein S.
    Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412
    [Abstract] [Full Text] [Related]

  • 13. The effect of sibutramine intake on resting and exercise physiological responses.
    Rotstein A, Inbar O, Vaisman N.
    Ann Nutr Metab; 2008 Dec; 52(1):17-23. PubMed ID: 18230966
    [Abstract] [Full Text] [Related]

  • 14. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K, Sibutramine in Hypertensives Clinical Study Group.
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [Abstract] [Full Text] [Related]

  • 15. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients.
    Finer N, Ryan DH, Renz CL, Hewkin AC.
    Diabetes Obes Metab; 2006 Mar; 8(2):206-13. PubMed ID: 16448525
    [Abstract] [Full Text] [Related]

  • 16. Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine.
    Hainer V, Kunesova M, Bellisle F, Hill M, Braunerova R, Wagenknecht M.
    Int J Obes (Lond); 2005 Feb; 29(2):208-16. PubMed ID: 15583700
    [Abstract] [Full Text] [Related]

  • 17. Sibutramine: its mode of action and efficacy.
    Finer N.
    Int J Obes Relat Metab Disord; 2002 Dec; 26 Suppl 4():S29-33. PubMed ID: 12457297
    [Abstract] [Full Text] [Related]

  • 18. [Sibutramin in obesity treatment (multicenter, open, prospective 12-month-long study)].
    Payer J, Hainer V, Ondrejka P, Kajtor Z.
    Vnitr Lek; 2004 Nov; 50(11):825-9. PubMed ID: 15648961
    [Abstract] [Full Text] [Related]

  • 19. Sibutramine-associated adverse effects: a practical guide for its safe use.
    Florentin M, Liberopoulos EN, Elisaf MS.
    Obes Rev; 2008 Jul; 9(4):378-87. PubMed ID: 18034790
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G, Cicero AF, Murdolo G, Piccinni MN, Fogari E, Bertone G, Ciccarelli L, Fogari R.
    Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.